SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Omkar Pharmachem Ltd

BSE: 532167 NSE: ISIN: INE501C01015
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Omkar Pharmachem Ltd belong to?
Omkar Pharmachem Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Omkar Pharmachem Ltd a good quality company?
Omkar Pharmachem Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Omkar Pharmachem Ltd undervalued or overvalued?
Omkar Pharmachem Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Omkar Pharmachem Ltd a good buy now?
Omkar Pharmachem Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd revenue growth is % for FY- , which is below its 5 year CAGR of 61% , indicating slower growth.
Q.2 Gross Profit margin of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Gross profit margin which is the profit after deduction of direct costs, is 50.9% for FY-2025 , which is above its 5 year median of 47.7% , indicating increasing margins.
Q.3 Operating Profit Margin of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 53.93% for FY-2025 , which is above its 5 year median of 52.59% indicating increasing margins.
Q.4 Net Profit Margin of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Net Profit Margin is 37.2% for FY-2025 , is above with its 5 year median of 36.63%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 50.9 47.7
Operating Profit Margin 53.93 52.59
Net Profit Margin 37.2 36.63
Q.5 Return on Asset of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Return on Asset is 2.11%, which is above its 5 year historical median of 2.06%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Return on equity is 2.15% for FY-2025 , which is in line with its historical median of 2.15%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Return on capital employed is 3.02% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Cash conversion cycle is 19 days, above its historical median of -12 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.06 0.06
ROE 2.15 2.15
ROCE 3.02 2.94
Cash Conversion Cycle 19 days -12 days
Q.9 Debt to Equity ratio of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Debt-to-Equity ratio is 0.01 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Omkar Pharmachem Ltd?
Omkar Pharmachem Ltd Debt to cash flow from operations is 0.49 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Omkar Pharmachem Ltd?
Promoters hold 0.03% of the Omkar Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Omkar Pharmachem Ltd vs industry peers?
Omkar Pharmachem Ltd revenue CAGR is 60.95% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 0.5 137.1
Gross Profit 0.3 15.1
Operating Profit 0.3 16
Net Profit 0.2 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.06 0.8
ROE 2.15 8.91
ROCE 3.02 11.59
Cash Conversion Cycle (days) 19.45 76

Valuation & price assessment

Q.1 Stock return of Omkar Pharmachem Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17.1% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 17.1% 7.3% 5.7% -1.7%
Q.3 Valuation ratios of Omkar Pharmachem Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 350 105.11 40.28
Price to Book 3.12 2.30 2.77
Price to Sales - 0.00 2.65
EV to EBITDA 138.74 35.08 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×